The primate SIGLEC12 gene encodes one of the CD33-related Siglec family of signaling molecules in immune cells. We had previously reported that this gene harbors a humanspecific missense mutation of the codon for an Arg residue required for sialic acid recognition. Here we show that this R122C mutation of the Siglec-XII protein is fixed in the human population, i.e., it occurred prior to the origin of modern humans. Additional mutations have since completely inactivated the SIGLEC12 gene in some, but not all humans. The most common inactivating mutation with a global allele frequency of 58% is a single nucleotide frameshift that markedly shortens the openreading frame. Unlike other CD33-related Siglecs that are primarily found on immune cells, we found that Siglec-XII protein is expressed not only on some macrophages, but also on various epithelial cell surfaces in humans and chimpanzees. We also found expression on certain human prostate epithelial carcinomas and carcinoma cell lines. This expression correlates with the presence of the non-frameshifted, intact SIGLEC12 allele. While SIGLEC12 allele status did not predict prostate carcinoma incidence, restoration of expression in a prostate carcinoma cell line homozygous for the frameshift mutation induced altered regulation of several genes associated with carcinoma progression. These stably transfected Siglec-XII-expressing prostate cancer cells also showed enhanced growth in nude mice. Finally, monoclonal antibodies against the protein were internalized by Siglec-XII-expressing prostate carcinoma cells, allowing targeting of a toxin to such cells.
Polymorphic expression of Siglec-XII in humans thus has implications for prostate cancer biology and therapeutics.
Sialic acids (Sias) are 9-carbon backbone sugar molecules typically found at terminal positions of glycan chains in Deuterostomes (vertebrates and some "higher" invertebrates), making them potentially important in recognition events (1) (2) (3) . One class of intrinsic Sia recognition proteins in vertebrates are Siglecs (Sialic acid binding immunoglobulin-like lectins). Siglecs are single-pass transmembrane proteins, with a Siabinding site in the extracellular N-terminal Immunoglobulin-like (Ig-like) V-set domain (4) (5) (6) (7) (8) (9) . Such V-set domains are followed by one or more C2-set Ig-like domains. Siglecs can signal through one or more tyrosine based signaling motif(s) in the cytoplasmic tail (5, 8, 9) .
CD33-related Siglecs (CD33rSiglecs) are encoded by a subset of SIGLEC genes clustered on chromosome 19 in humans and chimpanzees. They are homologous in sequence, and typically expressed on immune cells (10) . Analyses of genomic SIGLEC sequences across humans, chimpanzees, baboons, rats and mice showed that CD33rSiglecs are evolving rapidly (11) . This is particularly pronounced in the Sia recognizing Vset domain, suggesting that this domain is under the greatest selection pressure (11) (12) (13) (14) .
This study focuses on Siglec-12 (formerly Siglec-L1). We have shown previously that human Siglec-12 has an ArgCys (R122C) substitution mutation resulting in a protein unable to bind Sias (15) . By convention, the protein is referred to as Siglec-XII in humans, to differentiate it from Siglec-12 in other primates, where the Sia-binding arginine is present. The gene in both cases is referred to as SIGLEC12. Reversing this mutation in vitro restored Sia binding (15) . Thus, except for the R122C mutation, the Sia binding domain and reading frame was noted to remain intact.
The C-terminal signaling domain in CD33-related Siglecs has an Immunoreceptor Tyrosine-based Inhibitory Motif ( ITIM) or an Immunoreceptor Tyrosine-based Switch Motif (ITSM). ITIMs typically recruit the protein tyrosine phosphatases SHP-1 and SHP-2 or the lipid phosphatase SHIP-1, generally resulting in inhibitory downstream signaling (16) . The function of the ITSM motif in CD33-related Siglecs is unclear. Siglec-XII has an ITIM motif in its cytoplasmic C-terminal.
Analysis of chimpanzee, bonobo, gorilla and orangutan sequences show that they all have a functional SIGLEC12 gene with the key Arg residue intact (15) . Since humans and chimpanzees are typically ~99% identical in protein coding regions (17, 18) , but have significant physiological, anatomical and biomedical differences (such as a lower incidence of carcinomas in the latter) (19) , it is important to explore these genetic variations.
Here we ask if the R122C mutation is universal to humans, and explore the allele frequency of an additional polymorphic frameshift insertion mutation in the human SIGLEC12 gene, which results in a premature stop codon in some individuals. Using newly generated monoclonal antibodies against Siglec-XII, we also confirm and extended earlier work where we noted unexpected expression in epithelial cells, in addition to immune cells (15) . Finally, we describe the mechanistic and potential therapeutic significance of Siglec-XII expression in human carcinomas, particularly in prostate carcinomas.
Experimental Procedures
Cell Culture-All prostate cancer cell lines, PC-3, MDaPCa2b and LnCAP, and breast cancer cell lines MDA-MB-231 and MCF-7 were obtained from ATCC and grown as directed.
Genomic Sequencing of the First V-set Domain of SIGLEC12-The first V-set domain of SIGLEC12 was sequenced in 90 human individuals from diverse geographic. Characterization of the R122C mutation and the frequency of the frameshift mutation in globally distributed humans was performed on genomic DNA which was either kindly donated by Dr. Stephen Warren (Emory University) or Dr. Michael Hammer and the Y Chromosome Consortium (University of Arizona) (20) , or was obtained from the peripheral blood of healthy donors. Samples were amplified using primers 5'-UTR and 3'Chi3D as described (15) , using the Roche Long Template PCR kit, with cycling conditions of (a) 94°C denature for 10 seconds, (b) 5 cycles of annealing at 68°C for 30 seconds, (c) 5 cycles of annealing at 65°C for 30 seconds, and (d) 20 cycles of annealing at 62°C for 30 seconds, with at 3 minute extension at 68°C for each cycle, increasing by 20 seconds each cycle. Samples were sequenced on an ABI Prism 310 Genetic Analyzer using primer 5'UTR and primer 5'-CTTTGGCCTCTCTTGGAGCC-3', and analyzed with Sequencher (Gene Codes Corporation Ann Arbor, MI).
Analysis of Frameshift Mutation on Prostate Cancer and Control Samples-
The frameshift mutation polymorphism was also analyzed in 242 lymphocyte DNA samples from patients with prostate cancer and on 244 control DNA samples, from men who had been screened for prostate cancer. These genomic samples, isolated from whole blood using the QIAamp DNA Blood Maxi Kit (Qiagen) were a part of a cohort that has been previously used to assess risk for PCa using various genetic markers (21) . To determine the genomic status, the primers Forward 5'-ACCCCTGCTCTGTGGGAG AGT-3' and Reverse 5'-AGGATCAGGAGGGGC ATCCAAGGTGC-3' were used to amplify a 570bp region. The PCR conditions were 95°C for 3 min, (94°C-30 sec; 55°C-30 sec; 72°C-30 sec) for 35 cycles. The amplified DNA was sequenced using the Forward primer. The allele frequencies (presence/absence of frameshift) among the casecontrol groups were compared using the chisquare test. The odds ratio (OR) and its 95% confidence interval (CI) were estimated by unconditional logistic regression as a measure of the associations between genotypes and PCa risk, using R statistical software. Age was used as covariate. Statistical tests were two-sided and significance was set at p<0.05.
Analysis of Frameshift Mutation on
Prostate Cancer Paraffin Sections-Genomic DNA extracted from a set of 52 paraffin-embedded prostate cancer samples were used to compare Siglec-12 expression by Immunohistochemistry with its genomic status (i.e. presence of absence of frameshift). Paraffin tissue blocks were acquired as explained in the immunohistochemistry section, and genomic DNA was isolated. Paraffin block were cut in 5µM slices. Two such slices were used for each DNA prep. The slices were washed once with xylene and twice with ethanol (96-100%). The samples were air-dried and genomic DNA was extracted using the Macherey-Nagel nucleospin genomic DNA extraction kit from Clonetech. PCR was carried out using the forward primer, 5'-CAATGCAGAAGTCCGTGACGGTG CAGG-3' and the reverse primer 5'-AGGATCAGGAGGGGCATCCAAGGTGC-3' to obtain a 200 base pair product. PCR conditions were 1 cycle (94°C-2min), 11 cycles (94°C-10sec, 62°C-30sec, 1°C drop in annealing temperature per cycle, 68°C-45sec), 24 cycles, (94°C-15sec, 52°C-30sec, 68°C-45sec, 20 sec increase in extension time per cycle) followed by 68°C for 10mins. Sequencing was done using the reverse primer 5'-GGACATGTGTCCCGTCTCAGCCGT GC-3'.
Mouse Monoclonal Antibody Against Human Siglec-XII-A fusion protein Siglec-XII-Fc including the first three Ig-like domains of human Siglec-XII and the human IgG Fc domain was prepared as described (15) . The fusion protein was used to immunize mice to generate monoclonal antibodies (BD Pharmingen). Two final clones 1130 and 276 were obtained. Specificity was confirmed by lack of crossreactivity with Siglec-7-Fc. Studies were done using a mixture of the two clones or clone 276 or 1130 alone.
Immunohistochemistry studiesAnonymized archived paraffin blocks were obtained from the Cooperative Human Tissue Network (CHTN), or from the VA Medical Center, La Jolla, CA. Paraffin sections were deparaffinized and rehydrated, blocked for endogenous peroxidases and endogenous biotin. Epitopes were revealed using heat-induced antigen retrieval at pH 6.0 in citrate buffer. The slides were then incubated with the mouse anti-Siglec-XII antibodies. Bound antibody was detected using the CSA kit from DAKO following manufacturer's instructions. Digital photographs were taken using an Olympus BH2 microscope with an Olympus digital camera. The images were organized using Adobe Photoshop.
Flow Cytometry-Cells were stained with anti Siglec-XII monoclonal antibody 1130 or 276 or a mixture of the two to probe for Siglec-XII expression. Cells were lifted using 10mM EDTA and washed with 1% BSA-PBS. 500,000 cells were aliquoted and incubated with 1 µg of anti Siglec-XII monoclonal antibody 1130 or 276 or a mixture of the two for 1 hour on ice. Cells were washed with 1 ml 1% BSA-PBS and incubated with 1:100 GAM-RPE (Caltag) for 30 minutes on ice in dark. The cells were washed and resuspended in 400 µl of 1% BSA-PBS and read on FACSCalibur flow cytometer using Cellquest. The data was analyzed using FlowJo.
Establishing Stable Transfectants of Prostate Carcinoma Cells Expressing Siglec-XII-PC-3 cells were transfected with PvuI linearized hSIGLEC12-pcDNA3.1(-) or empty pcDNA3.1(-) in 6-well plates using Lipofectamine 2000 (Invitrogen). 48 hours after transfection, the cells were trypsinized and grown with 800 µg/ml G418. After growing about 1 month, expression of Siglec-12 was determined by flow cytometry. Four independent cell lines, from four independent transfections were obtained, two with hSIGLEC12 and two with empty pcDNA 3.1(-).
Microarray Gene Expression Profile Comparison of Transfected and Sham-Transfected
Prostate Carcinoma Cells-RNA was isolated from the stably transfected PC-3 cell lines using the RNeasy mini kit (Qiagen). cDNA was synthesized and hybridized to Genechip Human Genome U133 Plus 2.0 Array (Affymetrix). Quantity and quality of final total RNA were examined using a nanodrop and with the RNA QC-Standard Bioanalyzer (Agilent). 5ug of total RNA was used for cDNA synthesis, followed by in vitro transcription to incorporate biotin labels, and subsequent hybridization to Genechip Human Genome U133 Plus 2.0 Array (Affymetrix) was performed by the GeneChip Microarray Core (UC, San Diego) as described in the Affymetrix GeneChip protocol. The U133 Plus 2.0 interrogates ~ 54,000 probe ID's. The raw expression values were normalized using DNA Chip Analyzer build May 8, 2008 (dChip) (www.dchip.org), which is a Windows software package for probe-level analysis of gene expression microarrays (22) . Before further processing, the transcripts were filtered to 32,000 transcripts using the standard deviation for discrimination. The data was analyzed using Rank Products (RP) implemented within the Bioconductor project and the R program software (R is available as Free Software under the terms of the Free Software Foundation's GNU General Public License). Heatmaps were done using the dChip software. Functional analysis of genes was done using Ingenuity Pathways Analysis (IPA) from Ingenuity Systems, Inc.
Growth of Stable Prostate Carcinoma Transfectants as Tumors in Nude
Mice-1.5x10 6 stably transfected hSIGLEC12-PC3 and pcDNA3.1(-)-PC3 cells, suspended in 150µl PBS, were injected subcutaneously into the right and left flanks respectively, of male athymic/nude mice aged 12-16 weeks. Tumor length, breath and height were measured at regular intervals and volume was calculated using the standardized formula (/6)*Length*Width*Height. Mice were sacrificed and tumors extracted. Histopathological analysis included staining for CD45 and CD31. All mice experiments were approved by the UC San Diego, Institutional Animal Care and Use Committee (IACUC).
Anti-Siglec-XII Antibody-mediated Endocytotic Toxin Delivery into Prostate Cancer
Cells-2500 stably transfected hSIGLEC12-PC3 cells, were plated in 96-well plates in growth media. Next day, different amounts of MabZAP (Advanced Targeting Systems, San Diego, CA) (0 to 200ng) and anti Siglec-12 antibodies 1130 or 276 (0 to 130ng), were incubated together in cell growth media for 30 minutes on ice. After aspirating media from the cells, the MabZAPantibody mixture was added. Each combination of MabZAP-anti Siglec-XII antibody was repeated in triplicate. The cells were further incubated for 3 days. The number of viable cells in each well was determined colorimetrically using the CellTiter 96® AQ ueous One Solution Cell Proliferation Assay (Promega).
RESULTS

Mutation of Essential Arginine of Siglec-XII is Fixed in Humans.
In our initial SIGLEC12 paper (15), we reported that the few humans sequenced had a homozygous mutation that changed the Arg residue in the V-set Ig-like domain required for Sia recognition into a Cysteine. We now asked if this R122C mutation is fixed in human populations. We analyzed a set of human DNA samples representing globally diverse populations and found this mutation to be homozygous in all 90 humans tested. On the other hand, we previously reported that this R122C mutation was not present in multiple samples from "great apes", including bonobos, gorillas, chimpanzees and orangutans (15) . Thus, this functionally inactivating mutation apparently occurred prior to the common ancestor of all modern humans, and sometime after the split of the hominin lineage from that of the common ancestor of chimpanzees and bonobos.
Polymorphic Pseudogenization of SIGLEC12 in the Human Lineage. The R122C missense mutation universal to humans still leaves an open reading frame encoding a full-length Siglec-XII protein. However, we have now found additional mutations in many humans that would result in complete pseudogenization of SIGLEC12. As shown in Figure 1 , the commonest mutation was a single nucleotide insertion in the first V-set exon, which if translated, would result in a truncated protein of only 115 amino acids. This insertion mutation, a guanidine, occurs within a string of 3 other Gs between base-pairs 194 and 197 of the nucleotide sequence relative to the standard reference human genome sequence (23), so we cannot know precisely which G is the actual insertion. Evaluating the frequency of this mutation (SIGLEC12P; P for pseudogene) in human populations (Figure 2 ), we found a global allele frequency of 0.58, with allele frequencies ranging from 0.38 in sub-Saharan Africa, to 0.86 in Native American populations. Global genotype frequencies are 0.40 for homozygous frameshifted genotypes (designated G+/+), and 0.24 and 0.36 for homozygous wild-type (G-/-) and heterozygotes (G+/-), respectively.
Thus, following the fixation of the human-universal R122C mutation prior to the origin of humans, the SIGLEC12 gene has undergone an additional polymorphic pseudogenization in humans. In this regard, it is of interest that recent studies by others reported evidence for a selective sweep at the SIGLEC12 locus in humans (24) .
Macrophage and Epithelial Siglec-12 expression in some humans, and all chimpanzees.
A newly generated mouse monoclonal antibody was shown to recognize both human and chimpanzee Siglec-12-Fc protein in ELISA assays, and to have no cross-reactivity to Siglec-7-Fc. Flow cytometry showed no staining in human peripheral blood leukocytes, and low levels of monocyte staining in some chimpanzee samples (unpublished observations). Next, we looked for expression of Siglec-XII on paraffin sections of human and chimpanzee tissues using immunohistochemical methods. Cell pellets of 293T cells transfected with full length Siglec-XII were used as positive controls and with empty vector as negative controls for all immunohistochemistry experiments ( Figure S1 ). Strong macrophage and epithelial expression of Siglec-12 was seen in the chimpanzee prostate, pancreas, kidney and stomach ( Figure 3A) . Figure  3B shows expression of Siglec-12 on follicular dendritic cells in primate tonsil. As expected, not all humans showed expression, because of the frameshift insertion mutation. Among humans who did have an intact ORF, expression was observed on macrophage-like cells in the tonsils ( Figure 3C ) and also on epithelial cells of the kidney tubules and prostate epithelium. A possible explanation for the generally weaker expression in humans over chimpanzees even with the homozygous WT allele is that the extra Cys residue arising from the R122C mutation in the human protein might have a destabilizing effect on the formation of disulfide bonds during protein folding, resulting in lesser expression of mature properly folded protein. Regardless of the reason, this data confirms and extends our earlier observation using a chicken polyclonal antibody that human Siglec-XII is expressed on epithelial cells (15) .
Expression of Siglec-XII in GenotypicallyPositive Human Carcinomas and Carcinoma Cell
Lines. Given the expression of Siglec-XII in certain epithelial cells, we next analyzed its expression on human carcinomas (cancers of epithelial origin). Siglec-XII expression was indeed seen in many human prostate carcinoma specimens and also occasionally in breast carcinoma and in melanoma. In keeping with easily detectable expression in normal prostate epithelium, we found clear expression in prostate carcinomas (PCa), and we studied this cancer further. In the initial 52 PCa samples studied, there was a genotype to phenotype correlation, with no expression in samples in which both alleles were SIGLEC12P or frameshifted ( Figure 4A and Table  I ). Next, we looked for Siglec-XII expression in human breast and prostate carcinoma cell lines. Using flow cytometry, we found that while MDaPCa2b and LnCAP (PCa) and MCF-7 (breast cancer) lines were positive, MDaMb231 (breast cancer) and PC-3 (PCa) showed no expression ( Figure 4B ). As expected, lack of expression correlated with the presence of the homozygous genomic SIGLEC12P, i.e., the frameshift.
Siglec-XII Expression in a Genotypicallynull Prostate Carcinoma Cell Line Alters Expression of Multiple Genes Associated with
Carcinoma Progression. Given the prominent expression of Siglec-XII in some human PCa and its absence in others with the homozygous SIGLEC12P, we wondered if this had any functional consequences. As a first step towards addressing this question, we transfected the genotypically null PCa cell line, PC-3 with the intact human SIGLEC12 cDNA in the pcDNA3.1(-) expression vector, and established two lines with stable expression of cell surface Siglec-XII, using G418 selection (see Figure S2A , two empty vector transfected cell lines did not give a positive signal). We next studied total mRNA from both cell lines by microarray, looking for gene expression differences (see SI for details of analysis). As shown in Figure S2B we found limited but significant changes in gene expression between the SIGLEC12 and empty vector transfected cell lines. In all, 67 transcripts were identified as being down-regulated over the control upon Siglec-XII expression, at a false positive rate of 15%. Only MAP2K5 was upregulated.
Interestingly, Siglec-XII expression affected genes involved in carcinoma progression such as matrix metalloproteinase1 (MMT1), growth differentiation factor 15 (GDF-15/MIC-1) and RUNX2 ( Figure S2B and Supplementary cDNA or with empty vector were injected into the two flanks of nude mice. Tumor growth was followed for 69 days. As shown in Figure 4C , SIGLEC12 expressing PC-3 cells showed a difference in tumor volumes when compared to empty vector transfected cells. A one tailed t-test comparing the tumor volumes of SIGLEC12 PC-3 to pcDNA PC-3 tumors within each mouse showed a significant difference in mean size in 4 out of five mice at p < 0.05 (p = 0.0492, 0.036, 0.0196, and 0.0134 respectively). Thus the presence of the Siglec-XII resulted in significant increase in tumor volume. The same trend was seen in a second experiment, in which the Siglec-XII-positive cells produced tumors and the control transfected cells did not. Histological analysis of these tumors (done by CD31 and CD45 staining) showed that Siglec-XII positive tumors had decreased inflammatory cell infiltration.
SIGLEC12 Genomic Status Does Not Affect Prostate Cancer Incidence Risk.
We next asked whether the presence or absence of an open reading frame in the SIGLEC12 gene affected the risk of PCa in humans. The presence of the frameshift allele was determined in a EuropeanAmerican sample set of 242 PCa cases and 244 age-matched cancer-free controls. The PCa samples were obtained from men who were screened for PCa and consisted mainly of early stage cancer, although the samples were not necessarily selected on this basis. As shown in Table II , we found no significant association between SIGLEC12 genomic status and PCa incidence risk. No significant case/control difference in allele frequency distribution was observed (P=0.9). Logistic regression analysis confirmed that presence of the frameshift was not associated with any change in risk of PCa (p>0.05, Table II) .
Monoclonal Antibody Binding Induces Internalization of Cell Surface Siglec-XII And Targeting of a Toxin into Human Carcinoma
Cells. Previous studies have shown that Siglec-3, -5 and -9 undergo rapid internalization upon crosslinking with antibodies (25) (26) (27) . If a toxin is attached to such antibodies, toxin internalization also occurs and this results in cell death (27) . We wanted to see if Siglec-XII could utilized to deliver a toxin into cells and thus cause cell death. For this, we used MabZAP, a goat anti-mouse antibody that was conjugated to the toxin saporin (28) . Saporin is a ribosome inactivating protein from the seeds of Saponaria officinalis. Internalization of the Siglec would also deliver the mAb-MabZAP complex into the cell. To induce cell death, we incubated cells in a 96-well plate with primary antibody and MabZAP for 72 hours. Following this, cell viability was determined. Wells with both antibody and the MabZAP had only 35% of cells alive. Wells with MabZAP alone had nearly as many cells alive as wells with no treatment and wells with antibody alone showed some cell killing ( Figure 5B ). Although we only performed toxicity studies on the stably transfected SIGLEC12 PC-3 cell line as a proof of principle experiment, we looked for Siglec-XII internalization on the prostate cell line MDaPCa2b ( Figure 5B ), which natively expressed Siglec-XII and saw that the Siglec-XII was completely internalized. Since plant and bacterial protein toxins are capable of killing cells at very low intercellular concentrations, we surmised that under the right conditions, cell death would occur, even with small amounts of surface Siglec-XII on carcinoma cells.
DISCUSSION
The transmembrane position of Siglecs, along with their preference for binding sialic acids, the outermost sugars on cells surface glycans, make them an important part of the cell-cell communication system both within an organism and in between organisms such as host and pathogens. Previous work comparing SIGLEC loci in mice, rats, baboons, chimpanzees and humans showed that CD33-related Siglecs are evolving rapidly, especially in the Sia binding domain (11) . This rapid evolution could be in response to slight changes in the Sia molecular structure in the host itself and/or on surface of pathogens. Apart from SIGLEC12, other Siglecs that have undergone human specific changes in functional gene status, expression or ligand binding include SIGLEC1, SIGLEC5/14, SIGLEC6, SIGLEC7, SIGLEC9, SIGLEC11, SIGLEC13 and SIGLEC16 (29) . Such large-scale differences within a single class of gene indicates strong selection pressure on CD33-related SIGLEC loci in humans (29, 30) .
Although Siglec-12 in chimpanzees and the reverse mutated C122R human protein are shown to bind Sias, (15) its natural ligands are unknown. In humans, Siglec-XII with a Cys instead of the essential Arg is expressed as a nonSia binding full-length protein with cytosolic signaling domains intact. It is unclear if the protein can mediate normal downstream signaling in the absence the essential Arg, but our microarray experiment shows a large-scale gene downregulation upon stable expression. This suggests that Siglec-XII retains some downstream signaling activity. Despite the R122C mutation it is possible that Siglec-XII weakly recognizes sialic acids that result in the observed signaling effect. As shown in a previous work by others (31) , Cos-7 cells expressing Siglec-XII bind sialylated red blood cells marginally better (about 4-5 times) than non expressing Cos-7 cells -although this binding was undetectable when compared with a reverse mutated human C122R Siglec-XII (15) . This phenomenon might arise from other interactions between sialic acids and Siglecs, such as that between the sialic acid glycerol group and a conserved hydrophobic amino acid as seen in crystal structures of Siglec-5 (Tyr133), Siglec-7 (Trp132) and Sialoadhesin (Trp106) (32), (33) , (34) . This hydrophobic amino acid is conserved in all Siglecs (4). In addition there are other interactions between the sialic acid and the protein backbone (35) . It has also been shown that certain Siglecs, such as Siglec-11, Siglec-6 and Myelin-associated Glycoprotein still retain some Sia binding in the absence of the essential Arg (36), (37) , (38) . Siglec-XII might also have some residual sialic acid binding that might be enough to trigger a downstream signaling.
In addition to the R122C mutation, if the frameshift mutation is also present, there is no Siglec-XII expression, as confirmed by comparing genotype with immunohistochemistry.
Thus, individuals homozygous for SIGLEC12P will lack any Siglec-XII mediated signaling. This suggests a potential biochemical difference between genotypically different individuals and thus a potential target for natural selection.
Unlike other Siglecs, Siglec-XII is expressed on humans and chimpanzee epithelia, including human breast and prostate carcinomas. Epithelial carcinomas are rare in chimpanzees but occur at high frequencies in humans { (19, 29, 39, 40) . One might hypothesize that this difference results in part from the inability of human Siglec-XII to bind sialylated ligands, giving less efficient ITIM signaling. In contrast, chimpanzee Siglec-12 maintains sialic acid binding, thus giving full ITIM signaling and better inhibition. In keeping with this, we found it difficult to stably express chimpanzee Siglec-12 and human C122R Siglec-XII, i.e. the human Siglec reverse mutated to restore Sia binding, (unpublished observations). In contrast, expressing the non-Sia binding full length human Siglec-XII allows stable expression. Regardless of these speculations, microarray data shows that in presence of Siglec-XII, almost all observed changes in gene expression (with one exception) are downregulations. Functional analyses of the affected genes show that many of them are associated with cellular movement and cancer (Supplementary Table 1 ). Some genes known to be up-regulated in prostate cancers such as GDF15, TTF3, RUNX2, ITGB4, MMP1 and S100A9 are down-regulated in Siglec-XII expressing PC-3 cells. GDF15 (alternatively MIC-1) expressed by PCa cells, can disrupt cell adhesion and is associated with bone homeostasis (41, 42) . TFF3 is elevated in PCa, although its function is not clear (43) . RUNX2, a transcription factor, has an anti-apoptotic effect in early cancer, but contributes to subsequent bone metastasis (44) . ITGB4 overexpression is also associated with epithelial cancers and their proliferation (45) . IGFBP5 accelerates androgen independence of PCa cells, in vitro and in mouse models after androgen withdrawal (46) . Reducing IGFBP5 levels reduces cell proliferation after androgen withdrawal.
Another down-regulated gene is CDH1, which codes for E-Cadherin, important for adhesion and normal epithelium maintenance. Loss of E-cadherin expression is known to increase the likelihood of metastasis in epithelial carcinomas (47, 48) . Other studies show strong expression of E-cadherin in metastatis on PCa (49, 50) . The authors hypothesize that after a temporary loss of expression required for metastasis, the cancer cells regain E-cadherin expression for tumor establishment. Thus, the overall effect of CDH1 down-regulation is unclear.
The presence of the inhibitory ITIM motif in Siglec-XII could be the likely cause of the observed down regulation. A previous study (31) showed that Siglec-XII (called S2V in that paper) binds to the tyrosine phosphatases SHP-1 and SHP-2, in a phosphorylation dependent manner (co-immunoprecipitation worked only in the presence of pervanadate). Despite the R122C mutation, Siglec-XII was phosphorylated by the kinase c-src. The authors also showed that SHP-1 interaction with Siglec-XII was mediated by the ITIM domain in Siglec-XII. Since Siglec-XII has been shown to associate with SHP-1 and SHP-2 and that the interaction of SHP-1 is ITIM dependent, it is reasonable to conclude that the observed gene down regulation is due to the inhibitory ITIM domain. It is theoretically possible that these observed effects could vary, based on the amount of Siglec-XII expression. However, our two independently stable lines with different levels of Siglec-XII expression (differing by almost one order of magnitude, see Supp Figure1) still show a similar pattern of gene downregulation.
US population data shows that PCa is the most prevalent form of cancer diagnosed among men and the second leading cause of cancer related deaths (51) . Lack of symptoms during early stages makes periodic screening essential for timely treatment of this disease. The most common screening method, is the prostate specific antigen (PSA) test (52) , which has been shown to have a small effect on the mortality rate, while picking up false positives (53, 54) . Thus, there is a search for better markers to differentiate aggressive cancers from non-metastatic ones. For example, transcriptome sequencing to detect gene fusions (55) has resulted in discovery of gene fusions in prostate cancer (56) , especially the TMPRSS2-ERG gene fusions that occur in 50% of prostate cancers. The resulting over-expression of a chimeric fusion transcript encodes a truncated ERG product that can be detected by a rabbit anti-ERG monoclonal antibody (57) . In addition deletions of the PTEN (Phosphatase ad tensin homologue) gene have shown to correlate with aggressive and hormone resistant prostate cancer (58, 59) . A review recent advances in prostate cancer genetics can be found in Shen and AbateShen (60) .
Our own analysis of SIGLEC12 genomic status in PCa (mostly early stage PCa obtained during screening) and normal samples showed a similar allelic distribution in both groups, suggesting that presence or absence of the frameshift does not predict the incidence of PCa. Indeed, this region of the genome was not picked in a recent large genome-wide association study that reported seven new prostate cancer susceptibility loci (61) . However, based on our gene expression and tumor growth data, SIGLEC12 genomic and expression status could still have an effect on the long-term progression of the cancer and the eventual severity of the disease. Indeed, while the majority of patients diagnosed with early stage prostate cancer will develop microscopic disease with advancing age, only a minority will have metastatic disease (62).
For an initial indication of the role of Siglec-XII in prostate cancer development, we monitored the growth of human prostate cancer cells stably transfected with human SIGLEC12 or empty vector in nude mice. Cells expressing Siglec-XII showed a significant growth advantage over non-expressing cells. This small growth difference over 70 days (time period of the mouse experiment) could become pertinent over many years, the usual time that it takes for a clinically significant prostate cancer to develop in humans. It is currently unknown whether this result extends to humans but this is testable by association studies on large cohorts with known outcomes.
A recent study on polymorphic nonsense Single Nucleotide Polymorphisms (SNPs) in the human genome found SIGLEC12 to be one of the 12 outliers, among the 167 genes studied (24) . By calculating a statistical parameter called F ST , which is a measure of population differentiation, it was found that a majority of nonsense SNPs have a low F ST value (< 0.09), suggesting that these SNPs were at least mildly deleterious. SIGLEC12, on the other hand had a high F ST of 0.221 and a relatively high heterozygosity of 0.317, suggesting a balancing selection or a selective sweep. It is unlikely that PCa, which usually afflicts individuals in the post-reproductive period would affect this selective sweep. Future studies will work to uncover the selective target in or around the SIGLEC12 region on chromosome 19 .
All experiments in this study to Figure  S3) . Thus, the studies presented here are still relevant under conditions of native Siglec-XII expression. In the future we aim to study the effect of Siglec-XII more directly by knocking down its expression in endogenously expressing cell lines. Human Siglec-XII is expressed at low levels in the epithelium. Since 40% of human individuals are homozygous for SIGLEC12P and do not show any obvious phenotype, it can be concluded that this gene is not essential for survival, although its presence might become pertinent under special conditions. This apparently more specialized function makes it a target for invivo experimentation. In addition, Siglec-XII has a low and very narrow expression profile (it is expressed in only a very few cell types), thus making it a suitable candidate for antibodymediated targeting for drug delivery to cancer cells expressing it. Since Siglec-XII can be internalized upon antibody binding, a simultaneous delivery of a toxin attached to the antibody, could be a viable approach to future cancer therapy.
M., Kwon, E. M., Stern, M. C., Corral, R., Joshi, A. D., Shahabi, A., McDonnell, S. K., Sellers, T. A., Pow-Sang, J., Chambers, S., Aitken, J., Gardiner, R. A., Batra, J., Kedda, M. A., Lose, F., Polanowski, A., Patterson, B., Serth, J., Meyer, A., Luedeke, M., Stefflova, K., Ray, A. M., Lange, E. M., Farnham, J., Khan, H., Slavov, C., Mitkova, A., Cao Fig. 1 . Human-Specific Changes in the SIGLEC12 Gene. Alignment of exon1 of human and chimpanzee SIGLEC12. hSIGLEC12P is the allele with an extra G, resulting in a frameshift. hSIGLEC12 is the wild type allele. The signal peptide-coding region is underlined with a dashed line. The region with the extra G is underlined. The mutation from CGT (in chimp) to TGT (in humans) (boxed), results in an R122C mutation, which eliminates sialic acid binding. All human samples tested had the cysteine and thus do not bind sialic acid. hSIGLEC12P results in a premature termination codon, indicated by ***. Residues different from hSIGLEC12 have a grey background. 
FIGURE LEGENDS
TABLES
